AzTrials
AzTrials

Osteoporosis, OsteopeniaNCT03026660

Moringa Oleifera on Bone Density

A study testing Moringa Oleifera in people with Osteoporosis, Osteopenia and Postmenopausal Osteoporosis, run by Appalachian State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the effects of Moringa Oleifera on the structure and function of bone in post-menopausal women ingesting 1000 mg of Moringa Oleifera daily for 12 weeks. Read more about this study

Who is it for?
Ages 60 to 70 years, women onlyHealthy volunteers can take part
What is being tested?
Moringa Oleifera
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
1 siteUnited States
Study dates
Jul 2015to May 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 to 70 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Between 60 -70 years old
  • Female

Who cannot join

  • Fracture in non-dominant forearm/wrist or lower leg.
  • Currently taking blood thinners
  • Currently taking estrogen supplements
  • Have had a hysterectomy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Appalachian State University

    Boone, North Carolina, 28608

Other trials in United States

About this study

Official title: Effect of Moringa Oleifera on Bone Density in Post-Menopausal Women

The purpose of this study is to determine the effects of Moringa Oleifera on the structure and function of bone in post-menopausal women ingesting 1000 mg of Moringa Oleifera daily for 12 weeks.

Read the detailed description

Moringa Oleifera (M. Oleifera) is a tropical plant native to northern India, Pakistan, Himalayan regions, Africa, Central America, and Arabia that has been used for centuries in ethnic cultures all over the world. M. Oleifera is exceptionally rich in a variety of nutrients and medicinal phytochemicals, including those that promote bone density, such as vitamin D, calcium, phosphorus, magnesium and others. M. Oleifera also contains micronutrients that play a critical role in bone health and in calcium absorption, such as boron, vitamin C, magnesium, potassium, phosphorous and others. For instance, boron stabilizes and extends the half-life of vitamin D; magnesium (Mg) affects the activities of osteoblasts and osteoclasts, as well as bone homeostasis by modulating the concentration of parathormone and the activated form of vitamin D. Magnesium also contributes to bone structural development; vitamin K reduces bone turn over, improves bone strength and plays an essential role in osteocalcin carboxylation and vitamin C increases bone density and strength by increasing collagen formation and promotes healing during fracture. Collectively, these micronutrients in M. Oleifera are expected to significantly impact bone health. Given this knowledge, the purpose of the present study is to determine the effects of M. Oleifera on the structure and function of bone in post-menopausal women ingesting 1 gram of M. Oleifera daily for 12 weeks using DEXA scans.

The fresh young leaves of Moringa oleifera (about 2 years old) were collected by Dr. Joshua Idassi, from a field and high tunnel plots at the North Carolina Agriculture and Technical State University farm in July, 2014. Botanical identification and authentication were performed by Dr. Joshua Idassi, Natural Resources Specialist, from the Cooperative Extension Program, North Carolina A \& T. A voucher specimen (LUH 2923) was deposited in the herbarium of the University of Lagos, Akoka, Yaba, Lagos. Fresh leaves of M. Oleifera were air-dried for about 7 days at 30 ◦C and macerated into a fine powder.

Twenty-four untrained post-menopausal women (60-70 years old) were randomly assigned to either the control or placebo group (no program) or the experimental /treatment group (M. Oleifera supplement group). Both groups orally ingested 1 gram (1000 mg) daily of cabbage (placebo) or M. Oleifera (treatment group) leaf powder in capsules for 12 weeks. The bone scans were then taken pre-supplementation and after 12 weeks to determine the effects of M. Oleifera on various bone parameters, including bone mass density, bone mineral content, and select anthropomorphic results including weight, body fat percentage, and lean mass percentage.

The first visit to the laboratory by participants was utilized for providing them with general information and as a testing session. Specifically, the information session consisted of educating them on and obtaining signatures for informed consent, and conducting health history and physical activity questionnaire. The first testing session consisted of obtaining the pre-supplementation DEXA scans. The participants were then given six weeks' worth of their supplement. The subjects came back to the testing site again at six weeks (midway of supplementation) to pick up their supplement for the last six weeks and were then instructed on how to fill out a three-day diet log. The diet log was analyzed and averaged using the USDA Super Tracker online program. The third and last visit was 12 weeks after the start of supplementation and during this visit the second set of DEXA scans were obtained and the diet records were obtained. These records were used to determine the normal diet nutrients as well as caffeine intake of the participants.

DEXA scanning allows for the measurement of whole body bone density, as well as the specific density of the hip and femoral head. The subjects were laid on the DEXA machine scanner motionless for 6-10 minutes while the scan was performed. The first scan measured total body bone density, as well as the basic body composition. The subject were then asked to lay motionless for another 6-10 minutes while another DEXA scan was completed, which measured the bone density and characteristics of the hip and femoral head.The BMD, t-score and z-scores of the whole body were recorded, as well as the BMD, t-score, and z-scores of the right and left total hip and femoral necks. These data points were used to determine whether there were any significant differences between the two groups after the intervention period.

The supplementation of the M. Oleifera was began after the first visit which included the signing of the consent form, the performance of the pQCT and the DEXA scans. Once the subjects were scanned they (subjects) were randomly assigned to either the placebo or the M. Oleifera group. The M. Oleifera group was given the whole leaf M. Oleifera powder in capsule form at 1000mg daily for 12 weeks and similarly the control group was given the same amount of cabbage powder in capsule form and route. However, the placebo capsule consisting of cabbage had significantly lower levels of vitamins and nutrients compared to M. Oleifera. M. Oleifera was harvested and processed under optimal conditions and was carefully weighed on a scale and packed into capsules under sterile conditions. Each capsule for both groups contained 500 mg of the supplement, implying that each participant regardless of their weight took two capsules daily orally for 12 weeks. If they missed a day they were instructed not to double the dosage the next day. The placebo group was given the exact same instructions for consumption as the M. Oleifera group, and the study was conducted in a double blind manner. The dietary records were collected and analyzed to determine any significant differences between the two groups based on normal daily consumed nutrients.

Being tested
Moringa Oleifera, Cabbage Placebo
Keywords
Moringa Oleifera
Medical subject headings
Osteoporosis, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Moringa OleiferaDietary supplement

  • Cabbage PlaceboDietary supplement

Study groups in NCT03026660
Study groupRoleWhat they receive
Moringa treatmentExperimentalMoringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
Receives: Dietary Supplement: Moringa Oleifera
PlaceboPlacebo comparatorThe placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
Receives: Dietary Supplement: Cabbage Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bone Density

    Measured by Dual Energy X-Ray Absorptiometry

    Measured: 12 weeks after start of intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2017 (estimated)
  2. Study startJul 2015
  3. Primary completionFeb 2016
  4. Study completionMay 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03026660
Sponsor's protocol ID
15-0257
Status last verified
Jan 2017
First submitted
16 Jan 2017
Last updated
20 Jan 2017
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 Mar;22(3):465-75. doi: 10.1359/jbmr.061113.

    PubMed 17144789
  • Popoola JO, Obembe OO. Local knowledge, use pattern and geographical distribution of Moringa oleifera Lam. (Moringaceae) in Nigeria. J Ethnopharmacol. 2013 Nov 25;150(2):682-91. doi: 10.1016/j.jep.2013.09.043. Epub 2013 Oct 2.

    PubMed 24096203
  • Thurber MD, Fahey JW. Adoption of Moringa oleifera to combat under-nutrition viewed through the lens of the "Diffusion of innovations" theory. Ecol Food Nutr. 2009 May-Jun;48(3):212-25. doi: 10.1080/03670240902794598.

    PubMed 20161339
  • Singh V, Singh N, Pal US, Dhasmana S, Mohammad S, Singh N. Clinical evaluation of cissus quadrangularis and moringa oleifera and osteoseal as osteogenic agents in mandibular fracture. Natl J Maxillofac Surg. 2011 Jul;2(2):132-6. doi: 10.4103/0975-5950.94466.

    PubMed 22639499
  • Zeng FF, Xue WQ, Cao WT, Wu BH, Xie HL, Fan F, Zhu HL, Chen YM. Diet-quality scores and risk of hip fractures in elderly urban Chinese in Guangdong, China: a case-control study. Osteoporos Int. 2014 Aug;25(8):2131-41. doi: 10.1007/s00198-014-2741-2. Epub 2014 May 27.

    PubMed 24861906
  • Storm D, Eslin R, Porter ES, Musgrave K, Vereault D, Patton C, Kessenich C, Mohan S, Chen T, Holick MF, Rosen CJ. Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 1998 Nov;83(11):3817-25. doi: 10.1210/jcem.83.11.5289.

    PubMed 9814452
  • Nandave M, Ojha SK, Joshi S, Kumari S, Arya DS. Moringa oleifera leaf extract prevents isoproterenol-induced myocardial damage in rats: evidence for an antioxidant, antiperoxidative, and cardioprotective intervention. J Med Food. 2009 Feb;12(1):47-55. doi: 10.1089/jmf.2007.0563.

    PubMed 19298195

Questions about this trial

What is this clinical trial studying?

A study testing Moringa Oleifera in people with Osteoporosis, Osteopenia and Postmenopausal Osteoporosis, run by Appalachian State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Jan 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bone Density (time frame: 12 weeks after start of intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03026660, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in